Stifel Nicolaus Lowers HLS Therapeutics (TSE:HLS) Price Target to C$12.25

HLS Therapeutics (TSE:HLS) had its price objective cut by Stifel Nicolaus from C$15.00 to C$12.25 in a note issued to investors on Tuesday, BayStreet.CA reports. The brokerage currently has a “buy” rating on the stock. Stifel Nicolaus’ target price suggests a potential upside of 149.49% from the company’s previous close.

Separately, Raymond James lowered their price target on HLS Therapeutics from C$10.00 to C$9.00 and set a “market perform” rating on the stock in a report on Friday, July 28th.

HLS Therapeutics Stock Performance

TSE HLS traded down C$0.09 during trading hours on Tuesday, hitting C$4.91. The company’s stock had a trading volume of 1,767 shares, compared to its average volume of 26,174. HLS Therapeutics has a 12 month low of C$4.12 and a 12 month high of C$11.22. The company’s 50 day simple moving average is C$5.44 and its two-hundred day simple moving average is C$5.77. The company has a market cap of C$158.35 million, a P/E ratio of -4.38 and a beta of 1.09. The company has a debt-to-equity ratio of 84.42, a current ratio of 1.45 and a quick ratio of 1.01.

HLS Therapeutics (TSE:HLS) last released its quarterly earnings data on Thursday, August 10th. The company reported C($0.39) EPS for the quarter, missing the consensus estimate of C($0.17) by C($0.22). HLS Therapeutics had a negative return on equity of 20.38% and a negative net margin of 41.67%. The business had revenue of C$22.05 million during the quarter, compared to the consensus estimate of C$21.17 million. During the same quarter in the previous year, the business posted ($0.36) earnings per share. As a group, sell-side analysts expect that HLS Therapeutics will post -0.12 EPS for the current fiscal year.

About HLS Therapeutics

HLS Therapeutics Inc, a specialty pharmaceutical company, acquires and commercializes pharmaceutical products in the specialty central nervous system and cardiovascular markets in Canada, the United States, and internationally. The company's product portfolio includes Clozaril, an atypical antipsychotic for management of symptoms of treatment-resistant schizophrenia; Vascepa, an icosapent ethyl capsules for cardiovascular disease; and PERSERIS, an injectable risperidone product for the treatment of schizophrenia.